Gsk (GSK) Gross Profit (2009 - 2026)

Over the twelve months ended Sep 30, 2026, Gsk's Gross Profit came in at $56.19 billion, up 84.8% year-over-year; for the year ended Dec 31, 2025, it came in at $31.18 billion, up 9.3% from the prior year.

• Gross Profit has increased for five consecutive years, with a five-year compound annual growth rate of 8.1% (years ended Dec 2020 to Dec 2025).
• By year, Gross Profit came in at $28.54 billion in the year ended Dec 31, 2024 (+5.4%), $27.07 billion in the year ended Dec 31, 2023 (+10.6%), $24.47 billion in the year ended Dec 31, 2022 (+7.6%) and $22.75 billion in the year ended Dec 31, 2021 (+7.8%).
• Five-year quarterly Gross Profit spans a low of $5.78 billion in the quarter ended Dec 31, 2021 and a high of $31.46 billion in the quarter ended Dec 31, 2025.
• Year over year, Gross Profit has now increased in each of the last eight quarters, with growth averaging 48.5% over the last eight quarters.
• The high point for year-over-year Gross Profit in five years was the quarter ended Dec 31, 2025 (growth of 341.0%); the low point was the quarter ended Dec 31, 2021 (a decline of 21.3%).
• Per Business Quant data, the three quarters before the quarter ended Sep 30, 2026 came in at $8.24 billion (quarter ended Jun 30, 2026), $7.76 billion (quarter ended Mar 31, 2026) and $31.46 billion (quarter ended Dec 31, 2025).